Podcast | IL17Pod

Course Title for Certificate

Name

First NameLast Name

Email

example@example.com

What best describes your title?

How many years have you been in practice?

1. Psoriasis is driven by the:

2. The role of IL-17 in psoriasis is supported by:

3. Which of the following drugs are associated with a causal relationship for suicides and suicidal ideation?

4. Which of the following factors are associated with elevated liver function tests in patients with psoriasis?

5. In a pooled analysis of patients from the United States and Canada with moderate to severe psoriasis treated with bimekizumab for 5 years, which of the following safety outcomes showed the highest exposure-adjusted incidence rate (EAIR) per 100 patient- years in the BKZ total group?

6. A 55-year-old patient with moderate to severe plaque psoriasis and a history of prior biologic use is considering long-term bimekizumab therapy. Based on 4-year safety data from Phase 3/3b trials in responders achieving PASI 100 at Week 16, which statement best reflects the reported rates of oral candidiasis compared to the overall BKZ- randomized population?

Learning Objectives

Rows	Poor	Fair	Good	Very Good	Excellent
Review the MOA of IL-17 inhibitors and the biologic rationale for their use
Discuss the approved indications, use cases, and patient selection considerations for the use of IL- 17 inhibitors in dermatologic disease
Review and contextualize new information from EADV 2025 on the long-term monitoring of specific adverse effects attributed to IL- 17 blockers

Please provide us with feedback regarding your experience at the activity:

Rows	Poor	Fair	Good	Very Good	Excellent
Overall
Content
Usefulness

Do you feel this activity was fair, balanced, and free of commercial bias?

If no, please explain:

This educational activity will result in a change in my role as a healthcare team member.

Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:

What factors beyond clinical care that effect the health of your patients does your team experience?

Attestation:

AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits^TM.

AcademicCME designates this enduring material for a maximum of 0.75 CNE Contact Hours, including 0.75 Pharmacotherapeutic Contact Hours (Provider #P0491).

Clinicians should claim only the credit commensurate with the extent of their participation in the activity.

Date

Credits